Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.67%95 3-Year Book Growth Rate is 7.70% as of Jun. 2026, which is 17% below its 10-year median of 9.25. GuruFocus rates MIL:REC with a GF Score™ of 95/100 and a GF Value™ of €61.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 913 Drug Manufacturers companies, Recordati SpA ranks better than 61.12% on this metric.
During the past 12 months, Recordati SpA's average Book Value per Share Growth Rate was 14.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 9.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 9.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Recordati SpA was 14.20% per year. The lowest was 3.70% per year. And the median was 9.25% per year.
Recordati SpA (MIL:REC) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Recordati SpA 3-Year Book Growth Rate Related Terms
MIL:REC vs LLY, JNJ, ABBV: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 7.70% mean?
Recordati SpA (MIL:REC) has a 3-Year Book Growth Rate of 7.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Recordati SpA and its competitors. This is 17% below median its historical median of 9.25. Over the past decade, Recordati SpA's 3-Year Book Growth Rate has ranged from 3.70 to 14.20. According to the industry distribution chart, Recordati SpA ranks #355 out of 913 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Recordati SpA's 3-Year Book Growth Rate too high?
Recordati SpA's current 3-Year Book Growth Rate of 7.70% is 17% below median its 10-year median of 9.25. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 14.20. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Recordati SpA's value of 7.70% is 67.4% above this industry median. Based on the distribution chart, Recordati SpA ranks #355 out of 913 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 3-Year Book Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #355 out of 913 companies for 3-Year Book Growth Rate. This puts Recordati SpA in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Recordati SpA's value of 7.70% is 67.4% above this benchmark. Historically, Recordati SpA's own 3-Year Book Growth Rate has ranged from 3.70 to 14.20 over the past decade. While the company's 10-year median is 9.25 vs. the industry median of 4.60, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 913 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 3-Year Book Growth Rate of 7.70% is 67.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 3-Year Book Growth Rate is 7.70%, which is 17% below median its own 10-year median of 9.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.55, compared to a current price of €52.35 — trading 14.9% below its estimated fair value. The current 3-Year Book Growth Rate is 7.70%, which is 17% below median its 10-year median of 9.25 and 67.4% above the Drug Manufacturers industry median of 4.60. Recordati SpA's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 3-Year Book Growth Rate is 7.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €52.35 is trading 14.9% below its estimated GF Value™ of €61.55.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
3-Year Book Growth Rate: 7.70% (17% below median its 10-year median of 9.25)
GF Value™: €61.55 vs. price of €52.35 (14.9% below fair value)
Industry Position: 67.4% above the Drug Manufacturers median (#355 of 913)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
95GF Score
Get the complete analysis for MIL:REC
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
